×
SCYNEXIS Common Stock Net 2013-2025 | SCYX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
SCYNEXIS common stock net from 2013 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
SCYNEXIS Common Stock Net 2013-2025 | SCYX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
SCYNEXIS common stock net from 2013 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$69.3B
Zoetis (ZTS)
$67.6B
Takeda Pharmaceutical (TAK)
$47B
Daiichi Sankyo, - (DSNKY)
$46.1B
BeOne Medicines - (ONC)
$33.7B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$20B
Merck (MKKGY)
$16.8B
Shionogi (SGIOY)
$15.5B
United Therapeutics (UTHR)
$14B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$10.8B
IPSEN (IPSEY)
$10.6B
Madrigal Pharmaceuticals (MDGL)
$8.3B
Corcept Therapeutics (CORT)
$7.7B
Grifols, S.A (GRFS)
$7.3B
Ionis Pharmaceuticals (IONS)
$6.9B
Stevanato Group S.p.A (STVN)
$6.8B
Hikma Pharmaceuticals Plc (HKMPF)
$5.3B
Ono Pharmaceutical (OPHLF)
$5.1B
Soleno Therapeutics (SLNO)
$4.3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.8B
Hypermarcas (HYPMY)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$2.2B
Endo (NDOI)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B